



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/43

Date: 13th August 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Intimation for approval to acquire shares of Sudarshan Maven Pharma Private Limited
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have at their meeting held on 12th August 2026, inter-alia, approved to acquire 3,000 equity shares of Rs.10/- each of Sudarshan Maven Pharma Private Limited ('Sudarshan Maven') (CIN: U21001MH2024PTC431150), subsidiary of the Company, equivalent to 30.00% of the paid-up equity share capital of Sudarshan Maven. Upon completion of the acquisition, Sudarshan Maven would become a wholly-owned subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure-A.

You are requested to take the same on record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

Hemal Mehta
Chairman & Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.


E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Annexure-A.

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

SL NO	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	Name: Sudarshan Maven Pharma Private Limited (As on 31 st March 2026) Authorised Share Capital: Rs.25,00,000/- Paid Up Share Capital: Rs.1,00,000/- Revenue from Operations: Nil
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	Sudarshan Maven is primarily engaged in the manufacture, formulation, processing, development, import, export, distribution and trading of pharmaceutical and healthcare products
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Sudarshan Maven is in similar line of business activities as of the Company. Upon completion of acquisition, Sudarshan Maven would become a wholly-owned subsidiary of the Company.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	31 st December 2026
7	Nature of Consideration whether Cash consideration or share swap and details of the same	To be subscribed in cash.





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

8	Cost of acquisition or the price at which the shares are acquired.	Cost of acquisition shall be based upon valuation of Sudarshan Maven						
9	Percentage of shareholding control acquired and /or number of shares acquired	3,000 equity shares of Rs.10/- each (30.00% of the paid-up share capital) of Sudarshan Maven.						
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background:</u> Sudarshan Maven Pharma Private Limited was incorporated on 27th August 2024. Sudarshan Maven is primarily engaged in the manufacture, formulation, processing, development, import, export, distribution and trading of pharmaceutical and healthcare products Sudarshan Maven has not yet commenced its commercial activities. Last 2 years' turnover details: <table><tr><th>Financial Year</th><th>(Amount in Lakhs)</th></tr><tr><td>2025-26</td><td>NIL</td></tr><tr><td>2024-25</td><td>NIL</td></tr></table>	Financial Year	(Amount in Lakhs)	2025-26	NIL	2024-25	NIL
Financial Year	(Amount in Lakhs)							
2025-26	NIL							
2024-25	NIL							

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

